Business

Eli Lilly Commits $2.75 Billion to Fast-Track Drug Development with Insilico’s AI Technologies

March 29, 2026 · From the archive, written in the Professor's voice before our October 2026 redesign from statnews.com

What happened

Eli Lilly pledged up to $2.75 billion, including an immediate $115 million payment, to partner with Insilico Medicine. The collaboration aims to expedite drug discovery using Insilico’s multimodal deep learning and generative chemistry platforms, integrating diverse data types for comprehensive candidate design.

Why it matters

This partnership demonstrates the strategic use of multimodal AI—combining genomics, chemistry, and clinical data—to accelerate drug pipelines. It teaches that leveraging diverse datasets with advanced AI models can significantly reduce discovery timelines and improve candidate quality.

Who's doing it

Insilico and Eli Lilly’s collaboration has shown promising early results, reportedly identifying novel drug candidates in months rather than years, a significant productivity gain.

Try it

1. Utilize a multimodal AI platform like Insilico’s that accepts chemical, genomic, and clinical inputs.
2. Integrate diverse datasets to train or run predictive models.
3. Generate and prioritize drug candidates with combined insights, expecting faster and more accurate selections.

Read the original at statnews.com